Karen Akinsanya
Karen Akinsanya is a biomedical scientist and pharmaceutical researcher.[1] She is the President of R&D, Therapeutics at Schrödinger.[2][3] She is also the founder of New Jersey-based My Tech Learning.[4]
Early life and education
Akinsanya was born and raised in England.[5] She received her B.Sc. in biochemistry at Queen Mary College, University of London, and her Ph.D. in endocrine physiology from the Royal Postgraduate Medical School at Imperial College, University of London.[4][5]
Board member
As of 2022, Akinsanya serves on the board of Nautilus Biotechnology. She is also a member of the Board of Directors of the Imperial College Foundation, the Board of Trustees of Rockefeller University and serves on the Scientific Advisory Boards of Variant Bio and Thermo Fisher Scientific. She has served as a mentor at The Prince’s Trust in the United Kingdom.[4]
References
- ↑ Twenty extraordinary women in biopharma R&D who worked their way to the top | EndPoints News | November 11, 2019
- ↑ AlphaFold could be DeepMind’s AI assistant for drug discovery | WIRED | January 30, 2024
- ↑ Schrödinger’s Equation: Physics + Machine Learning = Drug Discovery | Genetic engineering and Biotechnology News | August 18, 2023
- ↑ 4.0 4.1 4.2 Nautilus Biotechnology Appoints Karen Akinsanya, Ph.D., to Board of Directors | Globe Newswire | March 31, 2022
- ↑ 5.0 5.1 Improving People's Lives | Diversity in Action magazine | May 1, 2020
